Carboplatin/Cisplatin+Pemetrexed+Nivolumab+Ipilimumab for 2 cycles and then maintenance with Nivolumab q21 and Ipilimumab q42 up to 2 years or disease progression or unacceptable toxicity: clinical trials recruiting now
Fewer than 3 recruiting trials found.
1
Recruiting trials
2
Conditions studied
0
US states with sites
1
Countries
Phase breakdown
Not applicable 1
Conditions being studied
| Condition | Trials |
|---|---|
| Lung cancer | 1 |
| PROMs | 1 |
Recruiting trials involving Carboplatin/Cisplatin+Pemetrexed+Nivolumab+Ipilimumab for 2 cycles and then maintenance with Nivolumab q21 and Ipilimumab q42 up to 2 years or disease progression or unacceptable toxicity
Common questions
How many recruiting trials involve Carboplatin/Cisplatin+Pemetrexed+Nivolumab+Ipilimumab for 2 cycles and then maintenance with Nivolumab q21 and Ipilimumab q42 up to 2 years or disease progression or unacceptable toxicity?
1 recruiting trial across 2 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.